PRESS-RELEASE ·Filed Oct 21, 2026
Press release · Earnings
Latest settled — T+1d
VNDA ▼ -0.99% at T+1d
NEUTRAL call -0.99% · α vs SPY -0.47% · entry $4.05 → $4.01
T+1d
-0.99%
call -0.99% · α -0.47%
$4.01
settled 6d ago
T+5d
Pending
in 7h
T+20d
Pending
in 21d
T+60d
Pending
in 3mo
Price Chart
Loading chart...
Executive Summary
Vanda Pharmaceuticals Inc. announced it will report its Q3 2026 results on October 28, 2026.
Key Facts
- Vanda Pharmaceuticals Inc. announced it will report its Q3 2026 results on October 28, 2026.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302916061 |
5 reports for VNDA
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $4.04 | awaiting T+20 | — | $3.99 (−1.24%) |
Oct 21, 2026 6d ago | Press Release | $4.05 | awaiting T+20 | — | $3.99 (−1.48%) |
Oct 9, 2026 18d ago | SC 13G/A | $4.54 | awaiting T+20 | — | $3.99 (−12.11%) |
Jul 29, 2026 12w ago | Press Release | $5.18 | awaiting T+20 | — | $3.99 (−22.97%) |
May 6, 2026 24w ago | 8-K | $6.39 $6.09 | ▼ −4.69% | ▼ −7.83% | $3.99 (−37.56%) |
Showing 5 of 5
US Market Status
Market Closed — Opens in 8h 21m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers